CYBIN INC.

HELP

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$10.3M

1 fund

Feb 17, 2026

$31.4M

1 fund

+206% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Feb 14, 2025

SC 13GRA Capital Management7.7%Mar 25, 2024

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 3,840,500Value: $31.4M

# Signal Note: OrbiMed Initiates $31.4M Position in CYBIN OrbiMed's new 3.84M share position signals conviction in CYBIN's psilocybin-assisted therapy pipeline, particularly for treatment-resistant depression (TRD) where the company is advancing Phase 2b studies. The $31.4M stake from a top-tier healthcare investor with strong track record in early-stage biotech de-risks execution risk and may indicate positive interim data visibility or upcoming catalysts in 2024-2025. Watch for Phase 2b TRD readout timing and any expanded indications (PTSD, anxiety) as near-term value inflection points.

Eventide Asset ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RNA2 funds IRON2 funds ARGX2 funds PRAX2 funds ALNY2 funds AXSM2 funds EWTX2 funds DYN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Eventide Initiates CYBIN Position Eventide's $10.3M entry into CYBIN suggests conviction in the company's psychedelic-assisted therapy pipeline, particularly COMP360 (psilocybin) for treatment-resistant depression (TRD), which completed Phase 2b dosing in 2023. The values-aligned investor's entry may signal confidence in upcoming Phase 3 data readout and regulatory pathway clarity, though near-term catalysts and competitive positioning versus Compass Pathways (CMPS) warrant monitoring.